European regulators on Friday recommended approving Pfizer Inc and Merck KGaA’s immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.
In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma.
Bavencio, known chemically as avelumab, belongs to a class of drugs called PD-L1 or PD-1 inhibitors that help the immune system to attack cancer by blocking a mechanism tumors use to evade detection.
Recommendations for marketing approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Martina D’Couto)
Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at email@example.com Contact no. 011-43720751